Drug interaction study for radiprodil halted early
NCT ID NCT06965881
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study looked at how two common drugs (carbamazepine and itraconazole) change the levels of radiprodil in the blood of 30 healthy adults. The goal was to understand safety and dosing for future use in neurological conditions like tuberous sclerosis. However, the study was terminated before completion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Radiprodil
- What could go wrong
- This was a very early (Phase 1) study in only 30 healthy people, not patients. It was terminated, so results may never be available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL CORTICAL DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
-
Q-Pharm Pty Ltd
Brisbane, Queensland, 4006, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Study links gum health to rare kidney diseases
- New drug radiprodil tested for tough seizures in two brain conditions
- Cannabis oil trial aims to tame seizures in rare genetic disorder
- New drug combo targets Hard-to-Treat cancers in early trial
- 20-Year study tests precision medicine for rare Brain-Skin disorders
- New pill aims to tame seizures in rare brain disorders